News

Nature9y
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma | Bone Marrow ... - Nature
We conducted a retrospective cohort study of individuals 0–21 years of age with HR-NBL treated with CEM or Bu/Mel preparative regimens for HDC-SCR at the Children’s Hospital of Philadelphia ...
National Institute for Health and Care Excellence1y
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) - NICE
Information. If NHS organisations wish to consider melphalan flufenamide with dexamethasone for this indication, they should follow the advice on rational local decision making in the NHS Constitution ...
ascopubs.org11y
High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric ... - ASCO Publications
To determine the maximum-tolerated dose of cyclophosphamide (CTX) when administered sequentially with melphalan 60 mg/m2/d for 3 days, followed by autologous bone marrow rescue (ABMR), in children ...
Nature18y
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model | Bone ... - Nature
Melphalan-based autologous stem cell transplant (Mel-ASCT) is a standard therapy for multiple myeloma, but is associated with severe oral mucositis (OM). To identify predictors for severe OM, we ...